Enanta Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a clinical-stage biotechnology company founded in 1995 and headquartered in Watertown, Massachusetts. The company is dedicated to the discovery and development of small-molecule drugs, primarily focusing on viral infections and immunological diseases. Enanta's business model is highly unique among development-stage biotechs due to its robust royalty stream. The company discovered glecaprevir, a key protease inhibitor that is a core component of AbbVie's blockbuster hepatitis C virus (HCV) regimen, Mavyret/Maviret. The ongoing royalties received from AbbVie under their collaborative development and license agreement help fund Enanta's wholly owned internal pipeline, reducing its reliance on dilutive capital markets.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead respiratory syncytial virus (RSV) candidates, zelicapavir (an N-protein inhibitor) and EDP-323 (an oral L-protein inhibitor), through late-stage clinical development and regulatory alignment.
Expected impact: Transition Enanta from a royalty-supported developer to a product-based biotech company with wholly owned commercial assets.
Expanding beyond virology into high-value immunology markets by developing oral small molecule inhibitors targeting key drivers of type 2 immune responses, specifically KIT (EDP-978), STAT6 (EPS-3903), and MRGPRX2.
Expected impact: Establish a diversified, wholly owned clinical portfolio addressing chronic spontaneous urticaria, atopic dermatitis, and other inflammatory diseases.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Discovered glecaprevir (part of AbbVie's MAVYRET/MAVIRET regimen for Hepatitis C), which generates ongoing royalty revenues that partially self-fund Enanta's internal R&D.
Terms: Enanta receives ongoing royalties on worldwide sales of MAVYRET/MAVIRET. Note: 54.5% of these future royalty payments (through June 2032, capped at 1.42x) were sold to OMERS in April 2023 for $200 million upfront.
Provided $200 million in non-dilutive upfront capital to strengthen Enanta's balance sheet and fund clinical development across its virology and immunology pipelines.
Terms: OMERS acquired the right to receive 54.5% of Enanta's future royalty payments from AbbVie on worldwide sales of MAVYRET/MAVIRET starting July 2023, capped at 1.42 times the purchase price ($284 million).